Novavax (NVAX) Says Phase 3 Trial of RSV F Vaccine for Infants via Maternal Immunization Will Continue; Provides Update on Phase 1/2 Trial of NanoFlu Vaccine

Go back to Novavax (NVAX) Says Phase 3 Trial of RSV F Vaccine for Infants via Maternal Immunization Will Continue; Provides Update on Phase 1/2 Trial of NanoFlu Vaccine
Novavax, Inc. (NASDAQ: NVAX) Delayed: 179.80 +3.56 (2.02%)
Previous Close $176.24    52 Week High $9.23 
Open $184.01    52 Week Low $1.16 
Day High $185.00    P/E N/A 
Day Low $178.38    EPS $-0.30 
Volume 3,019,312